Nobiletin Suppresses Cholangiocarcinoma Proliferation Via Inhibiting GSK3β

Overview

Journal Int J Biol Sci

Specialty Biology

Date 2022 Oct 20

PMID 36263164

Authors

Liping You

Jiacheng Lin

Zhuo Yu

Yihan Qian

Yuting Bi

Fang Wang

Lei Zhang

Chao Zheng

Jinghao Zhang

Wenxuan Li

Yaxuan Cai

Yueqiu Gao

Xiaoni Kong

Xuehua Sun

Affiliations

Soon will be listed here.

Abstract

Cholangiocarcinoma (CCA) is a type of hepatobiliary cancer characterized by uncontrolled cell proliferation, with a poor prognosis and high mortality. Nobiletin (NBT) is a promising anti-tumor compound derived from the peels of oranges and other citrus plants, citrus plant. But the effect of NBT on CCA remains unknown. Our data showed that NBT suppressed CCA cell proliferation and . Colony formation and Edu assay indicated that NBT inhibited cell proliferation. Cell cycle analysis showed that NBT arrested the cell cycle in G0/G1 phase. Target prediction showed that GSK3β was a direct target. Western blot and immunofluorescence confirmed that NBT reduced the phosphorylation of GSK3β. The antiproliferative effect of NBT was intercepted in GSK3β knockdown CCA cells. The cellular thermal shift assay (CETSA) showed NBT directly bound to GSK3β. Finally, NBT showed an anti-proliferative effect in tumor-bearing mice with no hepatotoxicity. NBT could inhibit CCA proliferation, and the pharmacological activity of NBT in CCA was attributed to its direct binding to GSK3β. We suggested that NBT might be a potential natural medicine in CCA treatment.

Citing Articles

Mechanistic Insights into the Anticancer Potential of Methoxyflavones Analogs: A Review.

Aidiel M, Abdul Mutalib M, Ramasamy R, Nik Ramli N, Tang S, Adam S Molecules. 2025; 30(2).

PMID: 39860214 PMC: 11768088. DOI: 10.3390/molecules30020346.

METTL protein family: focusing on the occurrence, progression and treatment of cancer.

Zhang H, Sun F, Jiang S, Yang F, Dong X, Liu G Biomark Res. 2024; 12(1):105.

PMID: 39289775 PMC: 11409517. DOI: 10.1186/s40364-024-00652-3.

Digitoxin inhibits ICC cell properties via the NF‑κB/ST6GAL1 signaling pathway.

Zhan Y, Wang R, Huang C, Xu X, Xiao X, Wu L Oncol Rep. 2024; 52(2).

PMID: 38940341 PMC: 11229393. DOI: 10.3892/or.2024.8762.

The Circadian Clock Component RORA Increases Immunosurveillance in Melanoma by Inhibiting PD-L1 Expression.

Liu D, Wei B, Liang L, Sheng Y, Sun S, Sun X Cancer Res. 2024; 84(14):2265-2281.

PMID: 38718296 PMC: 11247325. DOI: 10.1158/0008-5472.CAN-23-3942.

Nobiletin from citrus peel: a promising therapeutic agent for liver disease-pharmacological characteristics, mechanisms, and potential applications.

Cheng Y, Feng S, Sheng C, Yang C, Li Y Front Pharmacol. 2024; 15:1354809.

PMID: 38487166 PMC: 10938404. DOI: 10.3389/fphar.2024.1354809.

References

Razumilava N, Gores G . Cholangiocarcinoma. Lancet. 2014; 383(9935):2168-79. PMC: 4069226. DOI: 10.1016/S0140-6736(13)61903-0. View

Lee Y, Cheng T, Lee J, Chen J, Liao Y, Fong Y . Nobiletin, a citrus flavonoid, suppresses invasion and migration involving FAK/PI3K/Akt and small GTPase signals in human gastric adenocarcinoma AGS cells. Mol Cell Biochem. 2010; 347(1-2):103-15. DOI: 10.1007/s11010-010-0618-z. View

Sp N, Kang D, Joung Y, Park J, Kim W, Lee H . Nobiletin Inhibits Angiogenesis by Regulating Src/FAK/STAT3-Mediated Signaling through PXN in ER⁺ Breast Cancer Cells. Int J Mol Sci. 2017; 18(5). PMC: 5454848. DOI: 10.3390/ijms18050935. View

Jafari R, Almqvist H, Axelsson H, Ignatushchenko M, Lundback T, Nordlund P . The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc. 2014; 9(9):2100-22. DOI: 10.1038/nprot.2014.138. View

Shtutman M, Zhurinsky J, Simcha I, Albanese C, DAmico M, Pestell R . The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999; 96(10):5522-7. PMC: 21892. DOI: 10.1073/pnas.96.10.5522. View

Ohnishi H, Asamoto M, Tujimura K, Hokaiwado N, Takahashi S, Ogawa K . Inhibition of cell proliferation by nobiletin, a dietary phytochemical, associated with apoptosis and characteristic gene expression, but lack of effect on early rat hepatocarcinogenesis in vivo. Cancer Sci. 2004; 95(12):936-42. PMC: 11158043. DOI: 10.1111/j.1349-7006.2004.tb03180.x. View

Wu X, Song M, Gao Z, Sun Y, Wang M, Li F . Nobiletin and its colonic metabolites suppress colitis-associated colon carcinogenesis by down-regulating iNOS, inducing antioxidative enzymes and arresting cell cycle progression. J Nutr Biochem. 2017; 42:17-25. DOI: 10.1016/j.jnutbio.2016.12.020. View

Kawatkar A, Schefter M, Hermansson N, Snijder A, Dekker N, Brown D . CETSA beyond Soluble Targets: a Broad Application to Multipass Transmembrane Proteins. ACS Chem Biol. 2019; 14(9):1913-1920. DOI: 10.1021/acschembio.9b00399. View

Li M, Zhao H, Wu J, Wang L, Wang J, Lv K . Nobiletin Protects against Acute Liver Injury via Targeting c-Jun N-Terminal Kinase (JNK)-Induced Apoptosis of Hepatocytes. J Agric Food Chem. 2020; 68(27):7112-7120. DOI: 10.1021/acs.jafc.0c01722. View

10.

Wei D, Zhang G, Zhu Z, Zheng Y, Yan F, Pan C . Nobiletin Inhibits Cell Viability the SRC/AKT/STAT3/YY1AP1 Pathway in Human Renal Carcinoma Cells. Front Pharmacol. 2019; 10:690. PMC: 6635658. DOI: 10.3389/fphar.2019.00690. View

11.

Zhang X, Zheng K, Li C, Zhao Y, Li H, Liu X . Nobiletin inhibits invasion via inhibiting AKT/GSK3β/β-catenin signaling pathway in Slug-expressing glioma cells. Oncol Rep. 2017; 37(5):2847-2856. DOI: 10.3892/or.2017.5522. View

12.

Blechacz B, Gores G . Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008; 48(1):308-21. PMC: 2547491. DOI: 10.1002/hep.22310. View

13.

Dai J, Liang K, Zhao S, Jia W, Liu Y, Wu H . Chemoproteomics reveals baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis. Proc Natl Acad Sci U S A. 2018; 115(26):E5896-E5905. PMC: 6042128. DOI: 10.1073/pnas.1801745115. View

14.

Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z . Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013; 31(9):1188-95. DOI: 10.1200/JCO.2012.41.5984. View

15.

Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X . PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017; 45(W1):W356-W360. PMC: 5793840. DOI: 10.1093/nar/gkx374. View

16.

Banales J, Cardinale V, Carpino G, Marzioni M, Andersen J, Invernizzi P . Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016; 13(5):261-80. DOI: 10.1038/nrgastro.2016.51. View

17.

Mulvihill E, Assini J, Lee J, Allister E, Sutherland B, Koppes J . Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance. Diabetes. 2011; 60(5):1446-57. PMC: 3292317. DOI: 10.2337/db10-0589. View

18.

Ashrafizadeh M, Zarrabi A, Saberifar S, Hashemi F, Hushmandi K, Hashemi F . Nobiletin in Cancer Therapy: How This Plant Derived-Natural Compound Targets Various Oncogene and Onco-Suppressor Pathways. Biomedicines. 2020; 8(5). PMC: 7277899. DOI: 10.3390/biomedicines8050110. View

19.

Zhang L, Zhang X, Zhang C, Bai X, Zhang J, Zhao X . Nobiletin promotes antioxidant and anti-inflammatory responses and elicits protection against ischemic stroke in vivo. Brain Res. 2016; 1636:130-141. DOI: 10.1016/j.brainres.2016.02.013. View

20.

Walz A, Ugolkov A, Chandra S, Kozikowski A, Carneiro B, OHalloran T . Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer. Clin Cancer Res. 2017; 23(8):1891-1897. PMC: 5392367. DOI: 10.1158/1078-0432.CCR-15-2240. View